I. Executive Summary Drug repurposing — identifying new clinical indications for approved or investigational compounds — has moved from a […]
The US pharmaceutical market runs on a single, brutal equation: time equals money, and money equals survival. A company that
Welcome to the most volatile, high-stakes, and strategically critical discipline in modern business: the valuation of pharmaceutical and biotechnology companies.
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations Read Post »
1. Executive Summary and Scope Finding a winning generic drug opportunity requires more than scanning the Orange Book for upcoming
Patent cliffs destroy revenue overnight. Generic competition can erase 80% of a blockbuster’s sales within twelve months of loss of
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
I. The 505(b)(2) Pathway: What It Is and Why Analysts Keep Undervaluing It The 505(b)(2) pathway is the most structurally
The 505(b)(2) Goldmine: How Pharma Extracts Maximum IP Value from Modified Drugs Read Post »
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
Get fresh news and insights, drug patent expirations & more…
